Shares of uniQure (QURE) are under pressure on Thursday after the company announced it has entered into a licensing agreement with CSL Behring, providing the latter with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Following the news,… To see the rest of the story go to thefly.com. (See Story Here):(https://www.thefly.com/permalinks/entry.php/id3116817/-uniQure-plunges-as-takeover-hopes-dented-by-licensing-deal)